Thi Truc Anh Nguyen1, Lauren M Postlewait2, Chao Zhang3, Jane L Meisel4, Ruth O'Regan5, Sunil Badve1, Kevin Kalinsky4, Xiaoxian Li6. 1. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA. 2. Division of Surgical Oncology, Department of Surgery, Emory University, Atlanta, GA, USA. 3. Pediatric Biostatistics Core, Department of Pediatrics, Emory University, Atlanta, GA, USA. 4. Department of Hematology and Oncology, Emory University, Atlanta, GA, USA. 5. Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA. 6. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA. xli40@emory.edu.
Abstract
BACKGROUND: The management of estrogen receptor positive (ER+)/HER2- and lymph node (LN) negative breast cancers can be influenced by Oncotype DX recurrence score (RS) in the USA. However, the benefit of RS in T1 tumors (≤ 1 cm) is not clear. METHODS: We retrieved 199 T1 ER+/HER2-/LN- breast cancer diagnosed between 1993 and 2016 that had undergone RS testing. The median follow-up time was 51 months. We examined the disease-free survival (DFS) and distant metastasis and their association with RS and other clinicopathologic features. RESULTS: Of the 199 cases, 40 were T1a (≤ 0.5 cm) and 159 were T1b (> 0.5 cm to 1 cm) tumors. In the 40 T1a tumors, 11 would benefit from chemotherapy by the TAILORx study results. Of these T1a tumors, 36 were Nottingham grade 1/2, 3 were grade 3, and 1 was microinvasive carcinoma; 2 (5%) had local recurrence and 1 (2.5%) had distant metastasis to the bone. The only patient with T1a tumor (Nottingham grade 3, RS = 42) and distant metastasis to bone had received adjuvant chemotherapy. In the 159 T1b tumors, 25 would benefit chemotherapy by the TAILORx results. Of the T1b tumors, 149 were Nottingham grade 1/2 and 10 were grade 3. Nine (5.7%) had local recurrence and 2 (1.3%) had distant metastasis to bone and mediastinum, respectively. The two T1b tumors with distant metastasis had a RS 20 and Nottingham grade 2, and RS 27 and Nottingham grade 3, respectively. Both patients received adjuvant chemotherapy. In multivariate analysis of the entire cohort (T1a and T1b tumors), Nottingham tumor grade and receiving chemotherapy were significantly associated with DFS. In univariate analysis of the entire cohort, Nottingham tumor grade, receiving adjuvant chemotherapy, and RS were significantly associated with distant metastasis. CONCLUSION: This study demonstrates that the metastatic rate of T1a and T1b ER+/HER2-/LN- breast cancer is very low. Patients with low grade (1 or 2), T1a ER+/HER2-/LN- breast cancer may not need RS for treatment decision-making; however, in patients with high-grade T1a or T1b ER+/HER2-/LN- breast cancer, RS analysis should be strongly considered.
BACKGROUND: The management of estrogen receptor positive (ER+)/HER2- and lymph node (LN) negative breast cancers can be influenced by Oncotype DX recurrence score (RS) in the USA. However, the benefit of RS in T1 tumors (≤ 1 cm) is not clear. METHODS: We retrieved 199 T1 ER+/HER2-/LN- breast cancer diagnosed between 1993 and 2016 that had undergone RS testing. The median follow-up time was 51 months. We examined the disease-free survival (DFS) and distant metastasis and their association with RS and other clinicopathologic features. RESULTS: Of the 199 cases, 40 were T1a (≤ 0.5 cm) and 159 were T1b (> 0.5 cm to 1 cm) tumors. In the 40 T1a tumors, 11 would benefit from chemotherapy by the TAILORx study results. Of these T1a tumors, 36 were Nottingham grade 1/2, 3 were grade 3, and 1 was microinvasive carcinoma; 2 (5%) had local recurrence and 1 (2.5%) had distant metastasis to the bone. The only patient with T1a tumor (Nottingham grade 3, RS = 42) and distant metastasis to bone had received adjuvant chemotherapy. In the 159 T1b tumors, 25 would benefit chemotherapy by the TAILORx results. Of the T1b tumors, 149 were Nottingham grade 1/2 and 10 were grade 3. Nine (5.7%) had local recurrence and 2 (1.3%) had distant metastasis to bone and mediastinum, respectively. The two T1b tumors with distant metastasis had a RS 20 and Nottingham grade 2, and RS 27 and Nottingham grade 3, respectively. Both patients received adjuvant chemotherapy. In multivariate analysis of the entire cohort (T1a and T1b tumors), Nottingham tumor grade and receiving chemotherapy were significantly associated with DFS. In univariate analysis of the entire cohort, Nottingham tumor grade, receiving adjuvant chemotherapy, and RS were significantly associated with distant metastasis. CONCLUSION: This study demonstrates that the metastatic rate of T1a and T1b ER+/HER2-/LN- breast cancer is very low. Patients with low grade (1 or 2), T1a ER+/HER2-/LN- breast cancer may not need RS for treatment decision-making; however, in patients with high-grade T1a or T1b ER+/HER2-/LN- breast cancer, RS analysis should be strongly considered.
Authors: Amelia B Zelnak; Petros Nikolinakos; Jayanthi Srinivasiah; William Jonas; Andrew Pippas; Yuan Liu; Xiaoxian Li; Mylin Torres; Ruth M O'Regan Journal: Clin Breast Cancer Date: 2014-06-24 Impact factor: 3.225
Authors: Cletus A Arciero; Yi Guo; Renjian Jiang; Madhusmita Behera; Ruth O'Regan; Limin Peng; Xiaoxian Li Journal: Clin Breast Cancer Date: 2019-02-14 Impact factor: 3.225
Authors: Chad J Creighton; Xiaoxian Li; Melissa Landis; J Michael Dixon; Veronique M Neumeister; Ashley Sjolund; David L Rimm; Helen Wong; Angel Rodriguez; Jason I Herschkowitz; Cheng Fan; Xiaomei Zhang; Xiaping He; Anne Pavlick; M Carolina Gutierrez; Lorna Renshaw; Alexey A Larionov; Dana Faratian; Susan G Hilsenbeck; Charles M Perou; Michael T Lewis; Jeffrey M Rosen; Jenny C Chang Journal: Proc Natl Acad Sci U S A Date: 2009-08-03 Impact factor: 11.205
Authors: Bhuvanesh Dave; Sergio Granados-Principal; Rui Zhu; Stephen Benz; Shahrooz Rabizadeh; Patrick Soon-Shiong; Ke-Da Yu; Zhimin Shao; Xiaoxian Li; Michael Gilcrease; Zhao Lai; Yidong Chen; Tim H-M Huang; Haifa Shen; Xuewu Liu; Mauro Ferrari; Ming Zhan; Stephen T C Wong; Muthiah Kumaraswami; Vivek Mittal; Xi Chen; Steven S Gross; Jenny C Chang Journal: Proc Natl Acad Sci U S A Date: 2014-05-29 Impact factor: 11.205
Authors: Matthew Jennis; Che-Pei Kung; Subhasree Basu; Anna Budina-Kolomets; Julia I-Ju Leu; Sakina Khaku; Jeremy P Scott; Kathy Q Cai; Michelle R Campbell; Devin K Porter; Xuting Wang; Douglas A Bell; Xiaoxian Li; David S Garlick; Qin Liu; Monica Hollstein; Donna L George; Maureen E Murphy Journal: Genes Dev Date: 2016-03-31 Impact factor: 11.361